BELLICUM PHARMACEUTICALS, INC
BLCM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BLCM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2023.
Tracking 2 pipeline candidates for BELLICUM PHARMACEUTICALS, INC.
Run BELLICUM PHARMACEUTICALS, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BELLICUM PHARMACEUTICALS, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
12.3 months
OCF -$2M · Net income -$763K
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is BELLICUM PHARMACEUTICALS, INC's lead drug candidate?
BELLICUM PHARMACEUTICALS, INC's most advanced tracked candidate is bpx-601 (Phase 1/Phase 2) for metastatic castration-resistant prostate cancer and metastatic pancreatic cancer expressing PSCA.
Who is the CEO of BELLICUM PHARMACEUTICALS, INC?
Richard A. Fair is the chief executive officer of BELLICUM PHARMACEUTICALS, INC (BLCM).
What therapeutic areas does BELLICUM PHARMACEUTICALS, INC focus on?
BELLICUM PHARMACEUTICALS, INC develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.